MELINTA THERAPEUTICS INC (MLNT) Stock Price & Overview
NASDAQ:MLNT
The current stock price of MLNT is 0.5 null. Today MLNT is down by -5.7%. In the past month the price decreased by -68.15%. In the past year, price decreased by -90.57%.
MLNT Key Statistics
- Market Cap
- 6.876M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -9.47
- Dividend Yield
- N/A
MLNT Stock Performance
MLNT Stock Chart
MLNT Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to MLNT. When comparing the yearly performance of all stocks, MLNT is a bad performer in the overall market: 99.94% of all stocks are doing better.
MLNT Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to MLNT. MLNT has a bad profitability rating. Also its financial health evaluation is rather negative.
MLNT Earnings
MLNT Forecast & Estimates
MLNT Financial Highlights
Over the last trailing twelve months MLNT reported a non-GAAP Earnings per Share(EPS) of -9.469999999999999. The EPS increased by 19.95% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -393.39% | ||
| ROA | -140.14% | ||
| ROE | N/A | ||
| Debt/Equity | -1.47 |
MLNT Ownership
About MLNT
Company Profile
Melinta Therapeutics, Inc. develops and commercializes novel antibiotics designed to provide new and better therapeutic solutions. Melinta's lead product is Baxdela, an antibiotic approved by the US FDA for use in the treatment of acute bacterial skin and skin structure infections (ABSSSI). Melinta also has an extensive pipeline of preclinical and clinical stage products that were developed internally or assumed under the 2017 acquisition of Cempra, Inc. This pipeline includes many important classes of antibiotics, each targeted at a different segment of the anti-infective market. Melinta is headquartered in New Haven, CT.
Company Info
MELINTA THERAPEUTICS INC
44 WHIPPANY ROAD
MORRISTOWN NJ 07960
CEO: John H. Johnson
Phone: 908-617-1309
MELINTA THERAPEUTICS INC / MLNT FAQ
Can you describe the business of MELINTA THERAPEUTICS INC?
Melinta Therapeutics, Inc. develops and commercializes novel antibiotics designed to provide new and better therapeutic solutions. Melinta's lead product is Baxdela, an antibiotic approved by the US FDA for use in the treatment of acute bacterial skin and skin structure infections (ABSSSI). Melinta also has an extensive pipeline of preclinical and clinical stage products that were developed internally or assumed under the 2017 acquisition of Cempra, Inc. This pipeline includes many important classes of antibiotics, each targeted at a different segment of the anti-infective market. Melinta is headquartered in New Haven, CT.
What is the stock price of MELINTA THERAPEUTICS INC today?
The current stock price of MLNT is 0.5 null. The price decreased by -5.7% in the last trading session.
Does MELINTA THERAPEUTICS INC pay dividends?
MLNT does not pay a dividend.
What is the ChartMill rating of MELINTA THERAPEUTICS INC stock?
MLNT has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the PE ratio for MLNT stock?
MELINTA THERAPEUTICS INC (MLNT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-9.47).
What is MELINTA THERAPEUTICS INC worth?
MELINTA THERAPEUTICS INC (MLNT) has a market capitalization of 6.88M null. This makes MLNT a Nano Cap stock.
What is the ownership structure of MELINTA THERAPEUTICS INC (MLNT)?
You can find the ownership structure of MELINTA THERAPEUTICS INC (MLNT) on the Ownership tab.